TRML VS ALEC Stock Comparison

Performance

TRML
100/100

TRML returned 56.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

ALEC
10/100

ALEC returned -53.84% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Volatility

TRML
67/100

TRML has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

ALEC
44/100

ALEC has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Sentiment

TRML

"Sentiment" not found for TRML

ALEC
67/100

ALEC had a bullish sentiment score of 66.92% across Twitter and StockTwits over the last 12 months. It had an average of 10.30 posts, 9.70 comments, and 28.00 likes per day.

Technicals

TRML

"Technicals" not found for TRML

ALEC
11/100

ALEC receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

TRML

"Earnings" not found for TRML

ALEC
10/100

ALEC has missed earnings 13 times in the last 20 quarters.

Profit

TRML

"Profit" not found for TRML

ALEC
15/100

Out of the last 20 quarters, ALEC has had 3 profitable quarters and has increased their profits year over year on 2 of them.

All score calculations are broken down here to help you make more informed investing decisions

Tourmaline Bio, Inc. Common Stock Summary

Nasdaq / TRML

Healthcare

Biotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Alector, Inc. Common Stock Summary

Nasdaq / ALEC

Healthcare

Biotechnology

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Power up your portfolio